Government committed to transform Pakistan into a welfare state: Fawad

Islamabad, January 03, 2022 (PPI-OT): Federal Minister for Information and Broadcasting Chaudhry Fawad Hussain says PTI is committed to transforming Pakistan into a welfare state. Talking to the media in Faisalabad on Monday, he termed Sehat Card facility as a revolutionary programme in the history of Pakistan.

 

He said that the government under the leadership of Prime Minister Imran Khan is introducing the social welfare programme to improve the living standards of the people. The Federal Minister also said that PTI led government is emphasizing the use of EVMs because it wanted free, fair and transparent elections.

 

For more information, contact:

Ministry of Information and Broadcasting

Government of Pakistan

4th Floor, Cabinet Block, Pak. Secretariat, Islamabad, Pakistan

Tel: +92-51-9103557

Email: info@moib.gov.pk

Website: http://www.moib.gov.pk

 

Pakistan consistently advanced diplomatic objectives in 2021: FM

Islamabad, January 03, 2022 (PPI-OT): Foreign Minister Shah Mahmood Qureshi says Pakistan proactively and consistently advanced its diplomatic objectives on a range of diplomatic fronts, both bilaterally and multilaterally during the last year. He was presenting Year End Review of the Ministry of Foreign Affairs at a news conference in Islamabad on Monday.

 

The Minister said we have consolidated friendships and further strengthened bilateral relations with major powers and key partners across the regions. He said we successfully and effectively put forward our perspective and narrative on major foreign policy issues including Jammu and Kashmir dispute and the situation in Afghanistan.

 

Terming the year 2021 significant, Shah Mahmood Qureshi said several important developments and initiatives including Pakistan’s role for peace in Afghanistan, shift from geopolitics to geo-economics, Vision Central Asia, Engage Africa, public diplomacy and digital diplomacy have helped advance Pakistan’s foreign policy priorities.

 

The Minister said during the last year, we had eighty-five bilateral exchanges with over fifty countries. There were 35 senior leadership visits to Pakistan, 32 senior leadership visits by Pakistan, over 50 high level multilateral engagements, 25 public diplomacy engagements at Foreign Minister Level and 20 economic diplomacy engagements. He said five Pakistan sponsored or cosponsored resolutions were adopted by the United Nations. He said seventy years celebrations were held with six countries.

 

Shah Mahmood Qureshi said Pakistan played an important facilitating role for peace in Afghanistan and then for evacuation of foreigners from Kabul. Reiterating commitment for such a role in future, he said Pakistan has pledged five billion rupees humanitarian assistance for the Afghan people. He said the OIC countries also agreed on provision of humanitarian assistance to the Afghans in the recently held OIC Council of Foreign Ministers conference in Islamabad.

 

The Minister economic diplomacy has led to improvement by 39 points in Pakistan’s ranking in Ease of Doing Business, 7 percent increase in trade with Africa and improvement by 59 points in Pakistan’s Business Confidence Ranking. He said 2.9 billion dollars were deposited in Roshan Digital Accounts, 2 billion dollars invested in Naya Pakistan certificates, 24.1 percent increase was witnessed in home remittances; and 2 billion dollars increase was recorded in the export of information technology.

 

Regarding digital diplomacy, he said all 114 Missions have been brought online on social media platforms like twitter, Facebook and Instagram enabling greater transparency and access. The Foreign Minister said within our region, under SAARC COVID-19 Emergency Fund, Pakistan extended anti-pandemic medical equipment and other assistance to SAARC Member States including Sri Lanka, Nepal, Bangladesh, and Maldives.

 

He said SAARC Secretary-General visited Pakistan last week and Pakistan reaffirmed its willingness to host the 19th SAARC Summit. The Foreign Minister regretted that the prospects of durable peace and stability in our region, and the great potential for economic development and regional cooperation have been held hostage by the hegemonic and hostile behaviour of India.

 

For more information, contact:

Ministry of Information and Broadcasting

Government of Pakistan

4th Floor, Cabinet Block, Pak. Secretariat, Islamabad, Pakistan

Tel: +92-51-9103557

Email: info@moib.gov.pk

Website: http://www.moib.gov.pk

Satya Pal Malik has bitten hand that fed him: Omar

Srinagar, January 03, 2022 (PPI-OT): In Indian illegally occupied Jammu and Kashmir, National Conference leader, Omar Abdullah has said that former Governor of the territory, Satya Pal Malik has “bitten the hand that fed him” and asserted that people of Jammu and Kashmir can “certify” his “untrustworthiness”.

 

Omar Abdullah tweeted after Meghalaya Governor, Satya Pal Malik addressing a social function at Dadri in Haryana said that Prime Minister, Narendra Modi was “arrogant” when he met him to discuss the farmer protests and that he ended up having an argument with him. “This man was their hatchet man in J and K now he bites that hand that fed him. The people of J and K can certify the untrustworthiness of Mr Malik,” Omar Abdullah said in a tweet.

 

For more information, contact:

Kashmir Media Service

Phone: +92-51-4435548, +92-51-4435549

Fax: +92-51-4861736

Email: info@kmsnews.org

Website: www.kmsnews.org

 

Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus

– Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand

– ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection

– ASC11 is an oral direct-acting antiviral drug candidate targeting 3-chymotrypsin like protease (3CLpro), combined with ritonavir oral tablets, to treat SARS-CoV-2 infection

HANGZHOU and SHAOXING, China, Jan. 3, 2022 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672) today announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection. The Company’s COVID-19 pipeline currently includes (i) ritonavir oral tablet (100mg), an authorized product, (ii) ASC10, an oral RNA dependent RNA polymerase (RdRp) inhibitor and (iii) ASC11, an oral 3-chymotrypsin like protease (3CLpro) inhibitor.

The Company owns the only authorized ritonavir oral tablet in China, which passed bioequivalence study. The Company’s ritonavir oral tablet was approved in September, 2021 by China National Medical Products Administration (NMPA). As a pharmacokinetic booster of multiple antiviral protease inhibitors, a low dose ritonavir oral tablet (100mg) is a component of oral direct-acting antiviral drug Paxlovid (Nirmatrelvir+ritonavir). The Company applied the sophisticated formulation technology to significantly increase the human bioavailability of ritonavir which has a very poor solubility and successfully achieved human bioequivalence with the ritonavir oral tablets produced by the Originator, AbbVie. The Company is planning to file generic drug applications for registrations in multiple countries in the world. Ritonavir oral tablet annual production capacity has been expanded to 100 million tablets and can be further rapidly expanded based on market demand.

ASC10 is an oral direct-acting antiviral drug candidate targeting RdRp. In vitro data showed significant activity against SARS-CoV-2. ASC10 is an in-house discovered drug candidate with the global intellectual property and commercial rights. Compared to RdRp-targeted Molnupiravir which was approved by US Food and Drug Administration (FDA), ASC10 has a new and differentiated chemical structure. The Company has filed multiple compound and use patent applications. The data from animal studies demonstrated that ASC10 has higher bioavailability when compared to Molnupiravir. The Company plans to submit investigational drug applications (INDs) for clinical trials in China, USA etc. in the first half of 2022.

ASC11 is an oral direct-acting antiviral drug candidate targeting 3CLpro, in combination with the authorized ritonavir oral tablets produced by the Company, to treat SARS-CoV-2 infection. ASC11 is an in-house discovered drug candidate with the global intellectual property and commercial rights. Compared to 3CLpro-targeted Nirmatrelvir which was approved by US FDA, ASC11 has a new and differentiated chemical structure. The Company has filed the compound and use patent applications. The Company plans to submit INDs for clinical trials in China, USA etc. in the second half of 2022. The Company has extensive R&D experience in viral protease inhibitors and successfully developed and commercialized oral HCV protease inhibitor GANOVO® in combination with ritonavir oral tablets for the treatment of chronic hepatitis C.

“At the beginning of COVID-19 in 2020, based on its antiviral platform and R&D experience, the Company made the firm and rapid decision to invest in oral direct-acting antivirals R&D against RdRp and 3CLpro of SARS-CoV-2. Meanwhile, the Company accelerated the development effort to obtain the approval of ritonavir oral tablets in China and successfully achieved the authorization by China NMPA for ritonavir oral tablets,” said Dr. Jinzi J. Wu, Founder, Chairman and CEO of Ascletis, “The Company has tremendous experience in antiviral oral protease inhibitors and successfully developed the fixed-dose combination ASC09F (ASC09+ritonavir) to treat HIV infection, in addition to launching GANOVO®/Ritonavir combination for chronic hepatits C.”

Biden Unveils Plan to Boost Competition in US Meat Industry

The United States will issue new rules and $1 billion in funding this year to support independent meat processors and ranchers as part of a plan to address a lack of “meaningful competition” in the meat sector, President Joe Biden said on Monday.

The initiative comes amid rising concerns that a handful of big beef, pork and poultry companies have too much control over the American meat market, allowing them to dictate wholesale and retail pricing to profit at the expense of their suppliers and customers.

“Capitalism without competition isn’t capitalism. It’s exploitation,” Biden said. “That’s what we’re seeing in meat and poultry industries now.”

A recent White House analysis found that the top four meatpacker companies – Cargill, Tyson Foods Inc., JBS SA and National Beef Packing Co. – control between 55% and 85% of the market in the hog, cattle and chicken sectors.

The Department of Agriculture (USDA) will spend the $1 billion from the American Rescue Plan to expand the independent meat processing sector, including funds for financing grants, guaranteed loans and worker training, said Agriculture Secretary Tom Vilsack, who was speaking at an event with Biden.

USDA will also propose rules this year to strengthen enforcement of the Packers and Stockyards Act and to clarify the meaning of “Product of USA” meat labels, which domestic ranchers have said unfairly advantage multinational companies that raise cattle abroad and only slaughter in the United States.

Attorney General Merrick Garland, also speaking at the event, said “too many industries have become too consolidated over time,” and that the antitrust division of the Department of Justice has been chronically underfunded.

The Biden administration issued an executive order last year that advocated a whole of government approach to antitrust issues.

A central concern in agriculture has been meat prices, which have risen at a time when the White House is fighting inflation. An analysis in December by the White House economic council found a 120% jump in the gross profits of four top meatpackers since the pandemic began.

Reaction to plan

The meat industry has said the White House analysis was inaccurate and criticized the new plan.

National Chicken Council President Mike Brown called the plan “a solution in search of a problem.”

North American Meat Institute spokesperson Sarah Little said staffing plants remains the biggest issue for meatpackers and that the White House plan would not address it.

“Our members of all sizes cannot operate at capacity because they struggle to employ a long-term stable workforce,” she said. “New capacity and expanded capacity created by the government will have the same problem.”

Eric Deeble, policy director at the National Sustainable Agriculture Coalition, cheered the plan, calling it a “very positive step to ensure farmers and ranchers receive fair prices.”

The anticipated rulemaking under the Packers and Stockyards Act “could have a significant impact,” said Peter Carstensen, emeritus professor of law at University of Wisconsin-Madison and former antitrust attorney at the Department of Justice. But he noted that investment in independent processing itself would not address market concentration.

Austin Frerick, deputy director of the Thurman Arnold Project at Yale University, an antitrust research center, said the plan does not go far enough to tackle the power of the top meatpackers.

Source: Voice of America

Markets Open 2022 With Records, Apple Briefly Hits $3 Trillion in Value

Global stocks began 2022 in bullish fashion, with major bourses notching records and Apple’s valuation briefly hitting $3 trillion as investors monitor the COVID-19 pandemic and looming central bank rate decisions.

The CAC 40 index in Paris kicked off the rally with new intraday and closing records while Frankfurt’s DAX rose 0.9 percent in thin holiday trading. London and Tokyo were among global markets that were shuttered for holidays.

On Wall Street, both the Dow and S&P 500 ended at records as indices pushed higher.

Apple briefly climbed to $3 trillion in value, becoming the first U.S. company to hit that benchmark. The tech giant’s valuation later retreated, though its share price was 2.5 percent higher at the close.

“Welcome to 2022, which is looking like 2021 so far for the equity market,” market analyst Patrick O’Hare at Briefing.com said.

The market “looks as if it will keep riding the rails with the help of new inflows that are typically seen on the first trading day of a new month,” he added.

Monday’s landmarks come on the heels of a series of all-time highs in December as markets continue to bet the latest surge in COVID-19 cases won’t derail economic growth.

Comments from health experts characterizing the omicron variant as less lethal than earlier COVID-19 strains have boosted markets.

A bigger question mark is the shift in monetary policy, with investors now betting that the Federal Reserve will raise interest rates later this year.

The yield on the 10-year U.S. Treasury note vaulted above 1.6 percent Monday, the latest indication of this expectation.

A note from Briefing.com said the rise in yields may also reflect “an improving perspective on the economy.”

Oil prices

Elsewhere, oil prices finished a volatile session higher as eyes turn to the meeting of OPEC and other major producers on Tuesday.

So far OPEC+ has resisted pressure by top oil-consuming nations, such as the United States, to more aggressively boost production.

The 23 members of OPEC+ are expected to continue to stay the course and modestly boost output at their monthly meeting to be held via videoconference.

Source: Voice of America